Fujitsu Limited and the Resona Group companies Resona Bank, Limited and Saitama Resona Bank, Limited today announced the launch of a new web service designed to support customers in their home-buying process. The service is now available to customers of Resona Bank and Saitama Resona Bank.This development leverages the expertise of the Resona Group in home loan business and Fujitsu's internal and external best practices in digital transformation (DX). Fujitsu, primarily through its dedicated, collaborative BizDevOps team, supported the service from ideation to product planning, piloting, and development.Service development backgroundBuying a home represents a major life event, and the pressure to secure a property can often lead to rushed decisions based on incomplete information and in some cases even buyer’s remorse. This newly developed web service helps customers to make informed decisions from the earliest stages of their home search, even before applying for a mortgage, thereby ensuring a satisfying purchase.A first-of-its-kind service in Japan for visualizing, organizing, and comparing partners' home-buying preferencesWhile numerous home-buying assist tools exist, none offer a comprehensive solution for clarifying individual preferences and facilitating shared decision-making between partners. The new service provides a unique one-stop platform to visualize, organize, and compare preferences, making the home-buying process smoother and more collaborative. Key features include:1. Clarification of couples’ shared preferencesThis feature allows couples to share and compare their desired home specifications, including amenities, interior design, and layout, ensuring both partners feel satisfied with their final choice.2. Discovery of shared preferencesWith this feature, couples can record their preferences and observations for each room during property viewings, noting details about the kitchen, bathroom, and other areas.3. Ranking displayThis function calculates an overall score based on the information from the first two functions, displaying properties in order of preference. This simplifies the comparison process and helps couples quickly identify homes that best meet their needs.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Jan 15, 2025 - (JCN Newswire via SeaPRwire.com) - EEJA Ltd. (Headquarter: Chuo-ku, Tokyo; CEO: Akihiko Domae; hereafter “EEJA”), the main company operating TANAKA’s plating business, announced today that it would exhibit at the 39th NEPCON JAPAN, the electronics development and packaging exhibition scheduled to be held at Tokyo Big Sight from January 22–24, 2025. EEJA will premiere a range of new products in the field of plating technologies and processes to help meet rising needs in the electronics industry, including automotive electronic components and semiconductors.Technologies in demand have become increasingly sophisticated in recent years, with the primary usage domain for electronic components shifting from local to network usage. In contrast, the communications industry has shifted from 5G to 6G to support increased data volumes and faster communication speeds. The automotive industry has also changed, with the increased use of electronic components and semiconductors around the engine and demand for products able to pass testing in harsh environments in terms of characteristics such as heat and moisture resistance in particular.EEJA will exhibit several new plating technologies at NEPCON JAPAN, including PRECIOUSFAB Pd/Pt/Ru/Rh/Ir (a high hardness, wear-resistant platinum group plating process increasingly needed for in-vehicle electronic components), PRECIOUSFAB HG/GT/GS (a precious metal alloy plating process used as a means of reducing usage of precious metals that are becoming increasingly expensive, and to create further added value), MICROFAB series (a number of environment-friendly, non-cyanide processes), and SEADCAT (a direct patternable plating process that supports surface treatment of next-generation glass interposers that are essential for semiconductor packaging).Taking advantage of precious metals technologies acquired by TANAKA over many years in the industry, EEJA develops and provides the plating technologies and products that are essential in the electronics industry, from semiconductors to electronic components. With the demand for greater sophistication in the electronics industry, EEJA will continue contributing to technical innovations in the industry.Overview of EEJA's exhibition at 39th NEPCON JAPAN- Date and time: January 22–24, 2025 (10:00–17:00)- Venue: Tokyo Big Sight- Booth: E64-52, East Exhibition Halls- Main products on displayProduct nameOverviewPRECIOUSFAB Pd/Pt/Ru/Rh/Ir: High hardness, wear resistant platinum group plating processA plating process that achieves high reliability when used for contact parts of connectors, etc. that need durability and environment resistance, such as for in-vehicle applicationsMICROFAB Au2108/Au2168: Part of the MICROFAB series of environment-friendly, non-cyanide gold electroplating processes with improved stability of hardness and appearance (New Product)A plating process that does not use cyanide compounds, so will not only help in semiconductor manufacturing processes, but will also improve the plating work environments, which is expected to increase further in demand going forward. It is expected to improve product yields and reliability through stable appearance and hardness when forming gold bumps on increasingly fine-pitch and high-density wafersSEADCAT PRM200 series: Direct patterning plating technology (New Product) A plating technology that supports more material types than the SEADCAT100 seriesSEADCAT PRM200-MRG: Increased adhesiveness to LCPs and some fluororesins, with improved heat and moisture resistanceSEADCAT PRM200-MDI: Reduced copper diffusion through heat treatment after copper wire formation on polyimidesOptimization of primers has also enabled support for surface treatment of glass interposers.Refer to the following for detailed information on other plating processes and equipment.Plating Processeshttps://tanaka-preciousmetals.com/en/products/detail/plating-processes/Various plating processes are handled by EEJA Ltd.https://eeja.comPlating Equipmenthttps://tanaka-preciousmetals.com/en/products/detail/plating-equipment/Plating equipment is handled by group company Mitomo Semicon Engineering Co., Ltd.https://mitomo-semicon-eng.co.jp/en/home-2/EEJA Ltd.Headquarter: 2-6-6 Nihonbashi Kayabacho, Chuo-ku, TokyoEstablished: 1965CEO: Akihiko DomaeCapital: 100 million yenNet sales: 21.64333 billion yen (FY2023)Number of employees: 130 (including overseas sites) (as of December 31, 2023)Business activities: Development, manufacture, sales, and export of precious metal plating solutions and base metal plating solutions, additives, and surface treatment-related chemicalsHiratsuka Office: 5-50 Shinmachi, Hiratsuka-city, KanagawaOfficial Website: https://eeja.comAbout TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,355 employees, the group’s consolidated net sales for the fiscal year ending December, 2023, was 611.1 billion yen.Official Website: TANAKA PRECIOUS METAL TECHNOLOGIEShttps://tanaka-preciousmetals.com/en/Product inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press Release: http://www.acnnewswire.com/docs/files/2025115_EN.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Jan 15, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI) for weekly maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). A Prescription Drug User Fee Act (PDUFA) action date is set for August 31, 2025.The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector (AI). The injection process is expected to take, on average, 15 seconds. As part of the SC-AI 360 mg weekly maintenance regimen, patients who have completed the biweekly intravenous (IV) initiation phase, exact period under discussion with the FDA, would receive weekly doses that are expected to maintain the clinical and biomarker benefits.AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition.1,2,3 Only LEQEMBI works to fight AD in two ways by continuously clearing protofibrils and rapidly clearing plaque. With continuous administration, LEQEMBI clears highly toxic protofibrils* which can continue to cause neuronal injury even after amyloid-beta (Aβ) plaque has been cleared from the brain. Long-term three-year LEQEMBI data presented at the Alzheimer’s Association International Conference (AAIC) 2024 suggest that early and continuing treatment may prolong the benefit of therapy even after plaque is cleared from the brain.4The SC-AI is expected to be simple and easy for patients and their care partners to use, and may reduce the need for hospital or infusion site visits and nursing care for IV administration, which will make it easier to continue maintenance administration and may contribute to further simplifying the treatment pathway for AD.LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, Great Britain, Mexico, and Macau. In November 2024, the treatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval. Eisai has submitted applications for approval of lecanemab in 17 countries and regions. The US FDA accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly LEQEMBI IV maintenance dosing in June 2024 and set a PDUFA action date for January 25, 2025.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.5 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.6 INDICATIONLEQEMBI® [(lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.CONTRAINDICATIONLEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients of LEQEMBI. Reactions have included angioedema and anaphylaxis.WARNINGS AND PRECAUTIONS AMYLOID-RELATED IMAGING ABNORMALITIESMedications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.Incidence of ARIASymptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.Incidence of ICHICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.Risk Factors of ARIA and ICHApoE ε4 Carrier StatusOf the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE ε4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers.Radiographic Findings of CAANeuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA.The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.Concomitant Antithrombotic or Thrombolytic MedicationIn Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.Radiographic Severity With LEQEMBIMost ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).Monitoring and Dose Management GuidelinesBaseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.HYPERSENSITIVITY REACTIONSHypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.INFUSION-RELATED REACTIONS (IRRs)IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.In the event of an IRR, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids. ADVERSE REACTIONSThe most common adverse reactions reported in ≥5% with LEQEMBI and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%). Copyright 2025 JCN Newswire via SeaPRwire.com.